会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
    • 糖基化抗性的花青素和相关的缀合物,组合物,核酸,载体,宿主细胞,生产方法和使用非糖基化花青素的方法
    • US06780847B2
    • 2004-08-24
    • US09815079
    • 2001-03-22
    • Michael R. Boyd
    • Michael R. Boyd
    • A61K3804
    • A61K38/164A61K47/645A61K47/6817A61K47/6833A61L2/0082A61L2/0088A61L2/18A61L2/186A61L2/23C07K14/195
    • An isolated and purified nucleic acid molecule that encodes a protein or peptide comprising at least nine contiguous amino acids of SEQ ID NO:2, wherein the at least nine contiguous amino acids comprise amino acids 30-32 of SEQ ID NO: 2 which have been rendered glycosylation resistant and wherein the at least nine contiguous amino acids have antiviral activity, a vector comprising such an isolated and purified nucleic acid molecule, a host cell or organism comprising the vector, a method of producing an antiviral protein or antiviral peptide, the antiviral protein or antiviral peptide itself, a conjugate comprising the antiviral protein or antiviral peptide, and compositions comprising an effective amount of the antiviral protein, antiviral peptide, antiviral protein conjugate or antiviral peptide conjugate. Further provided is a method of inhibiting prophylactically or therapeutically a viral infection, specifically an influenza viral infection, of a host.
    • 编码包含SEQ ID NO:2的至少九个连续氨基酸的蛋白质或肽的分离和纯化的核酸分子,其中所述至少九个连续氨基酸包含已经被SEQ ID NO:2的氨基酸30-32 提供的糖基化抗性并且其中所述至少九个连续氨基酸具有抗病毒活性,包含这种分离和纯化的核酸分子的载体,包含载体的宿主细胞或生物体,产生抗病毒蛋白或抗病毒肽的方法,抗病毒 蛋白质或抗病毒肽本身,包含抗病毒蛋白或抗病毒肽的缀合物,以及包含有效量的抗病毒蛋白,抗病毒肽,抗病毒蛋白缀合物或抗病毒肽缀合物的组合物。 进一步提供的是预防或治疗宿主的病毒感染,特别是流感病毒感染的方法。
    • 10. 发明授权
    • Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
    • 抗髓磷脂碱性蛋白的肽特异性和髓鞘碱性蛋白质肽对多发性硬化患者的施用
    • US06252040B1
    • 2001-06-26
    • US09055263
    • 1998-04-06
    • Kenneth G. WarrenIngrid Catz
    • Kenneth G. WarrenIngrid Catz
    • A61K3804
    • C07K14/4713A61K38/00
    • Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administratin of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP has been localized to an area between amino acid 86 and amino acid 95.
    • 人髓磷脂碱性蛋白(h-MBP)的分子量为18.5KD,含有170个氨基酸残基。 已经生产了长度为约8至25个残基并覆盖蛋白质整个长度的合成肽。 发现h-MBP(抗MBP)的抗体在体外被合成肽中和,其跨越从约氨基酸残基61至约氨基酸残基106的h-MBP。涵盖氨基酸 (约1至63个残基)和羧基(约117至162个)末端未中和纯化的抗MBP。 肽MBP(75-95),MBP(86-95)或MBP(82-98)的鞘内给药产生游离(F)抗MBP的完全结合中和,结合(B)水平没有变化。 对照肽MBP35-58对F或B抗MBP水平没有影响。 MBP(75-95),MBP(86-95)或MBP(82-98)的静脉内给药导致F和B CSF抗MBP水平显着下降。 对鞘内或静脉内的MS患者施用MBP合成肽没有任何不良神经系统的影响,并没有发生全身并发症。 MS抗MBP的MBP表位已经定位于氨基酸86和氨基酸95之间的区域。